KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection
KSHV 亚单位候选疫苗可引发针对 KSHV 感染的有效体液免疫反应
基本信息
- 批准号:10559659
- 负责人:
- 金额:$ 85.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-03-22 至 2026-02-28
- 项目状态:未结题
- 来源:
- 关键词:AdultAnimal ModelAnimalsAntibodiesAntibody ResponseAntibody titer measurementB-Cell LymphomasB-LymphocytesCD34 geneCallithrixCallithrix jacchus jacchusCarcinogensCellsChildClassificationDataDeveloped CountriesDeveloping CountriesDevelopmentDiseaseDoseEndotheliumEnzyme-Linked Immunosorbent AssayEpitheliumFK506FibroblastsFundingFutureGlycoproteinsGoalsHIV/AIDSHerpesviridaeHerpesviridae InfectionsHerpesvirus VaccinesHumanHuman Herpesvirus 8IatrogenesisImmuneImmune responseImmunizationImmunizeImmunocompetentImmunocompromised HostImmunoglobulin GImmunosuppressionIn VitroIncidenceIndividualInfectionInternational Agency for Research on CancerKaposi SarcomaLicensingMalignant NeoplasmsMarketingMeasuresMediatingMembrane GlycoproteinsModelingModified Vaccinia Virus AnkaraMonkeysMusMyeloid CellsOncogenicOryctolagus cuniculusOutcomePatternPersonsPhase I Clinical TrialsPolyvalent VaccinePopulationPreventive vaccinePrimary InfectionPropertyRegimenResearchRouteSafetySalivaSeroprevalencesSubunit VaccinesTacrolimusTestingTimeTransplant RecipientsUnited States National Institutes of HealthVaccinationVaccinesViralViral ProteinsViremiaVirus DiseasesVirus-like particleWild Type Mousecancer preventioncell typedesignearly childhoodefficacy evaluationhumanized mouseimmunogenicimmunogenicityimmunological statusimmunosuppressedin vivoinnovationneutralizing antibodynonhuman primatenovel vaccinespermissivenessplacebo grouppre-clinicalpreventprimary effusion lymphomaprophylacticresponsesuccessunvaccinatedvaccine candidatevaccine developmentvaccine evaluationvector
项目摘要
PROJECT SUMMARY
Kaposi sarcoma-associated herpesvirus (KSHV) has been classified as a direct carcinogen by the International
Agency for Research on Cancer because of its ability to cause Kaposi sarcoma (KS) and two rare types of
B-cell lymphoma. KS frequently occurs among iatrogenic or HIV/AIDS-induced immunosuppressed individuals.
To date, there is no licensed KSHV vaccine that can prevent primary infection and subsequent malignancies.
Our objective in this application is to optimize the inclusion of key KSHV glycoproteins (gps), which are
involved in epithelial, endothelial, fibroblast and B-cell entry, into multivalent subunit vaccine candidates that
can stimulate neutralizing antibody (nAb) immune responses to prevent or limit KSHV infection and KSHV+
cancers in vivo. This application builds on my recently completed NCI K01 CA184388-05 research on KSHV
entry mechanisms and vaccine development. Recently, we showed that in vitro, the KSHV glycoprotein gH is
essential for viral infection of epithelial, endothelial, and fibroblasts cells, but not B cells. Notably, we and other
have also shown that both monoclonal and polyclonal Abs to KSHV glycoproteins K8.1, gB, and gH/gL can
neutralize KSHV infection of diverse permissive human cells in vitro. Building on this success, we have
generated quadrivalent virus-like particles (KSHV-LPs) incorporating the four glycoproteins critical for viral
entry (K8.1, gB and gH/gL). In this application we will use wild-type and humanized mice and common
marmoset (Callithrix jacchus) models to test the hypothesis that purified KSHV-LPs delivered directly or
through immunization with a modified vaccinia Ankara vector (MVA-KSHV-LPs) will elicit robust protective nAb
responses to KSHV infection and its associated malignancies. The premise of our proposal is built on strong
evidence that 1) infection with KSHV does not occur during early childhood, as is typical for other
herpesviruses, opening a window of opportunity for vaccination and 2) Abs against the KSHV glycoproteins
K8.1, gB, and gH/gL can neutralize KSHV infection. Furthermore, the permissiveness of humanized mice and
marmosets to KSHV infection offers an ideal platform to test candidate vaccines. Thus, a polyvalent vaccine
that induces prophylactic neutralizing Abs responses will not only be an invaluable candidate vaccine in
preventing KSHV infection, but also of utmost importance in preventing KSHV-associated diseases. We will
provide evidence for the safety of our candidate KSHV vaccine based on three pre-clinical animal models as
prerequisite data for an IND application for a phase I clinical trial. In the long term, the success of our approach
will introduce a new vaccine to the market with a potential for reducing global incidence of KSHV+
malignancies (>44,000 cases/year), and the possibility of limiting KSHV infection and associated malignancies
in developing countries or eradicating them from developed countries where KSHV seroprevalence is <10%.
项目总结
卡波西肉瘤相关疱疹病毒(KSHV)已被国际组织列为直接致癌物
癌症研究机构,因为它能引起卡波西肉瘤(KS)和两种罕见的
B细胞淋巴瘤。KS经常发生在医源性或HIV/AIDS诱导的免疫抑制的个体中。
到目前为止,还没有获得许可的KSHV疫苗可以预防初次感染和随后的恶性肿瘤。
我们在这项应用中的目标是优化关键的KSHV糖蛋白(GPS)的包含,这些糖蛋白是
参与上皮细胞、内皮细胞、成纤维细胞和B细胞进入多价亚单位候选疫苗
可刺激中和抗体(NAB)免疫反应,预防或限制KSHV感染和KSHV+
体内的癌症。此应用程序基于我最近完成的关于KSHV的NCI K01 CA184388-05研究
进入机制和疫苗开发。最近,我们发现在体外,KSHV糖蛋白Gh是
对上皮细胞、内皮细胞和成纤维细胞的病毒感染是必需的,但对B细胞不是。值得注意的是,我们和其他人
还表明,抗KSHV糖蛋白K8.1、Gb和Gh/Gl的单抗和多克隆抗体都可以
在体外中和不同允许的人类细胞感染KSHV。在这一成功的基础上,我们有
产生的含有对病毒至关重要的四种糖蛋白的四价病毒样颗粒(KSHV-LP)
条目(K8.1、GB和Gh/Gl)。在这项应用中,我们将使用野生型和人源化的小鼠和普通的
毛猴(Callithrix Jacchus)模型检验纯化的KSHV-LPs直接或
通过用改良的痘苗病毒安卡拉载体(MVA-KSHV-LP)免疫将产生强大的保护性NAB
对KSHV感染及其相关恶性肿瘤的反应。我们建议的前提是建立在强大的
有证据表明:1)KSHV感染不会发生在儿童早期,这是其他儿童的典型情况
疱疹病毒,为疫苗接种和抗KSHV糖蛋白的抗体打开了一扇机会之窗
K8.1、Gb、Gh/gl可中和KSHV感染。此外,人源化小鼠的容忍性和
绒猴对KSHV的感染为测试候选疫苗提供了一个理想的平台。因此,一种多价疫苗
诱导预防性中和抗体反应不仅将是一种非常有价值的候选疫苗
预防KSHV感染不仅对预防KSHV相关疾病至关重要。我们会
基于以下三种临床前动物模型为我们的候选KSHV疫苗的安全性提供证据
IND申请I期临床试验的先决条件数据。从长远来看,我们方法的成功
将向市场推出一种有可能降低全球KSHV+发病率的新疫苗
恶性肿瘤(44,000例/年),以及限制KSHV感染和相关恶性肿瘤的可能性
在发展中国家或从KSHV血清阳性率为10%的发达国家根除KSHV。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Javier Gordon Ogembo其他文献
Correction: HPV genotyping by L1 amplicon sequencing of archived invasive cervical cancer samples: a pilot study
- DOI:
10.1186/s13027-024-00589-0 - 发表时间:
2024-06-19 - 期刊:
- 影响因子:2.800
- 作者:
Charles D. Warden;Preetam Cholli;Hanjun Qin;Chao Guo;Yafan Wang;Chetan Kancharla;Angelique M. Russell;Sylvana Salvatierra;Lorraine Z. Mutsvunguma;Kerin K. Higa;Xiwei Wu;Sharon Wilczynski;Raju Pillai;Javier Gordon Ogembo - 通讯作者:
Javier Gordon Ogembo
Javier Gordon Ogembo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Javier Gordon Ogembo', 18)}}的其他基金
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10623087 - 财政年份:2021
- 资助金额:
$ 85.1万 - 项目类别:
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection
KSHV 亚单位候选疫苗可引发针对 KSHV 感染的有效体液免疫反应
- 批准号:
10376277 - 财政年份:2021
- 资助金额:
$ 85.1万 - 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10318876 - 财政年份:2021
- 资助金额:
$ 85.1万 - 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10474478 - 财政年份:2021
- 资助金额:
$ 85.1万 - 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10737872 - 财政年份:2021
- 资助金额:
$ 85.1万 - 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10627167 - 财政年份:2021
- 资助金额:
$ 85.1万 - 项目类别:
Unmasking the roles of viral glycoproteins in oral transmission of KSHV
揭示病毒糖蛋白在 KSHV 口腔传播中的作用
- 批准号:
10599690 - 财政年份:2021
- 资助金额:
$ 85.1万 - 项目类别:
A multivalent prophylactic and therapeutic vaccine against EBV infection and EBV-associated malignancies
针对 EBV 感染和 EBV 相关恶性肿瘤的多价预防性和治疗性疫苗
- 批准号:
10247243 - 财政年份:2020
- 资助金额:
$ 85.1万 - 项目类别:
Characterization of Epstein-Barr virus monoclonal antibodies as tools for diagnosing and prevention of EBV infection in transplant settings
EB 病毒单克隆抗体作为移植环境中诊断和预防 EBV 感染工具的表征
- 批准号:
9797160 - 财政年份:2018
- 资助金额:
$ 85.1万 - 项目类别:
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies
一种预防 EBV 感染和 EBV 相关恶性肿瘤的新型 VLP 疫苗
- 批准号:
9302981 - 财政年份:2017
- 资助金额:
$ 85.1万 - 项目类别:
相似海外基金
Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
- 批准号:
495434 - 财政年份:2023
- 资助金额:
$ 85.1万 - 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
- 批准号:
10586596 - 财政年份:2023
- 资助金额:
$ 85.1万 - 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
- 批准号:
10590479 - 财政年份:2023
- 资助金额:
$ 85.1万 - 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
- 批准号:
10642519 - 财政年份:2023
- 资助金额:
$ 85.1万 - 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
- 批准号:
23K06011 - 财政年份:2023
- 资助金额:
$ 85.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
- 批准号:
10682117 - 财政年份:2023
- 资助金额:
$ 85.1万 - 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
- 批准号:
10708517 - 财政年份:2023
- 资助金额:
$ 85.1万 - 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
- 批准号:
10575566 - 财政年份:2023
- 资助金额:
$ 85.1万 - 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
- 批准号:
23K15696 - 财政年份:2023
- 资助金额:
$ 85.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
- 批准号:
23K15867 - 财政年份:2023
- 资助金额:
$ 85.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists














{{item.name}}会员




